Enamel Lesion Detection With New DX Tool

September 10, 2026 updated by: Colgate Palmolive

Early Enamel Lesion Detection and Management With a New Diagnostic Tool

The primary objective of this 12-week study is to test BlueCheck's ability to identify enamel lesions consistently, and its ability to track changes in these lesions over time.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

5

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Georgia
      • Lithonia, Georgia, United States, 30038
        • Dental Dreams, LLC
        • Contact:
        • Principal Investigator:
          • Zerita Buchanan, DDS, MPH

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Signed Informed Consent/Assent Form.
  • Male and female subjects aged 13 years or older.
  • Availability for the duration of the study.
  • Good general health and good oral health based on the opinion of the study investigator.
  • Subjects must have active enamel lesions and no cavities requiring immediate restoration in the mouth.
  • Subjects must be candidates for high fluoride toothpaste treatment.

Exclusion Criteria:

  • Subjects with fixed or removable orthodontic appliances or removable partial dentures.
  • Obvious signs of periodontal disease or any condition that the dental examiner considers exclusionary from the study.
  • Cavities.
  • Concurrent participation in another oral clinical study.
  • Self-reported pregnant and/or lactating women, or those planning to become pregnant during the study.
  • History of allergies or sensitivity to personal care consumer products or their ingredients.
  • Medical condition which requires premedication prior to dental visits/procedure.
  • Significant oral soft tissue pathology, excluding plaque-induced gingivitis.
  • Dental prophylaxis within 30 days prior to study start.
  • Subjects who must receive dental treatment during the study dates.
  • Immunocompromised individuals (HIV, AIDS, immunosuppressive drug therapy).
  • Use of smokeless tobacco, vaping, or e-cigarettes or suspected substance abuse.
  • Current smokers (if former smoker, should have stopped at least 1 month prior to Visit 1).
  • Subjects who have an infectious disease and/or other blood borne diseases (Hepatitis series, HIV, tuberculosis).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Test Group
This is a monadic study with one arm. All subjects will receive the intervention.
Device: BlueCheck
BlueCheck, a carious lesion detection formulated device, will be used to track enamel lesions for patients who are newly receiving a high fluoride toothpaste.
Drug: Prevident 5000ppm Booster Plus Toothpaste
This clinical study is testing the ability of BlueCheck to detect enamel lesions over time. In order to show changes in lesions, subjects will be prescribed Prevident 5000ppm Booster Plus Toothpaste

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Enamel Lesions per BlueCheck
Time Frame: Baseline, 4 weeks, and 12 weeks
Number of enamel lesions counted after using BlueCheck
Baseline, 4 weeks, and 12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Self-perceived reactions to BlueCheck application
Time Frame: Baseline, 4 weeks, and 12 weeks
Questionnaire clinician and subject feedback on the BlueCheck application
Baseline, 4 weeks, and 12 weeks
Enamel Lesions per Xray
Time Frame: Baseline, 4 weeks, and 12 weeks
Number and location of visible enamel lesions on Xray
Baseline, 4 weeks, and 12 weeks
Enamel lesions per intraoral camera
Time Frame: Baseline, 4 weeks, and 12 weeks
Number and location of enamel lesions detected by an intraoral camera using a caries mode
Baseline, 4 weeks, and 12 weeks
White spots
Time Frame: Baseline, 4 weeks, and 12 weeks
Number and location of visible white spots per examiner's identification
Baseline, 4 weeks, and 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Colgate Palmolive

Collaborators

Dental Dreams, LLC

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 15, 2026

Primary Completion (Estimated)

December 20, 2026

Study Completion (Estimated)

December 20, 2026

Study Registration Dates

First Submitted

September 2, 2026

First Submitted That Met QC Criteria

September 10, 2026

First Posted (Actual)

September 14, 2026

Study Record Updates

Last Update Posted (Actual)

September 14, 2026

Last Update Submitted That Met QC Criteria

September 10, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CRO-2025-CaseStudies-BC-GJ

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe